ライフサイエンスコーパス: adjusted hazard ratio

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 2014 period) compared to chemotherapy alone (adjusted hazard ratio 0.24, 95% CI 0.07-0.85, and 0.10,

2 0-day readmissions, and had lower mortality (adjusted hazard ratio 0.57, 95% confidence interval 0.55

3 ction was associated with improved survival [adjusted hazard ratio 0.61; (95% confidence interval (CI

4 nd 55% in the non-invasive management group (adjusted hazard ratio 0.68, 95% CI 0.55-0.84).

5 use was associated with lower risk of death (adjusted hazard ratio 0.85 [95% CI, 0.75-0.96]) and card

6 ated with significantly increased mortality (adjusted hazard ratio 0.99, 95% confidence interval 0.62

7 ssociated with a 41% reduction in mortality (adjusted hazards ratio 0.59, 95% confidence interval 0.4

8 s with AH50 greater than or equal to median (adjusted hazard ratio = 0.59 [95% CI, 0.41-0.87]).

9 r accounting for microvascular inflammation (adjusted hazard ratio =0.967; 95% CI: 0.948 to 0.986; ha

10 than with guided treatment (3.0% vs. 17.9%; adjusted hazard ratio, 0.15; 95% CI, 0.09 to 0.26), but

11 48) and to multidrug-resistant tuberculosis (adjusted hazard ratio, 0.19; 95% confidence interval, 0.

12 t decreased the risk of death or transplant (adjusted hazard ratio, 0.30; 95% confidence interval [CI

13 acts exposed to drug-sensitive tuberculosis (adjusted hazard ratio, 0.30; 95% confidence interval, 0.

14 % CI, 15.9-21.5%] versus 36.2% [33.2-39.3%], adjusted hazard ratio, 0.44 [95% CI, 0.32-0.61]).

15 compared with the CAC-present (6.9%) group (adjusted hazard ratio, 0.45 [95% CI, 0.34-0.60]; P<0.000

16 had significantly lower graft failure rates (adjusted hazard ratio, 0.47; 95% confidence interval, 0.

17 TAVR compared with conservative management (adjusted hazard ratio, 0.53 [95% CI, 0.47-0.60], P<0.001

18 with a lower risk of the composite outcome (adjusted hazard ratio, 0.59 [0.36-0.97]; P=0.036; and 0.

19 e 26.21% and 19.87% versus 10.82% and 6.43% (adjusted hazard ratio, 0.60; 95% CI, 0.42 to 0.86; P = .

20 ) or with more rapid MERS-CoV RNA clearance (adjusted hazard ratio, 0.65 [95% CI, .30-1.44]; P = .29)

21 ogression to MMI-defined atrophy (20 events: adjusted hazard ratio, 0.65/logit increase; P = 0.002) b

22 95% confidence interval [CI], -5.0 to -3.6; adjusted hazard ratio, 0.69; 95% CI, 0.62 to 0.76).

23 .9 percentage points [95% CI, -8.1 to -5.7]; adjusted hazard ratio, 0.73 [95% CI, 0.67 to 0.81]).

24 n in the nonsteroid group (83.54% vs 87.77%; adjusted hazard ratio, 0.73; 95% CI, 0.70-0.76; p < 0.00

25 T plus memantine versus WBRT plus memantine (adjusted hazard ratio, 0.74; 95% CI, 0.58 to 0.95; P = .

26 nce, -6.1% [95% CI, -12.6% to 0.4%]; primary adjusted hazard ratio, 0.79 [95% CI, 0.63 to 1.004]; pri

27 preceding eras (2015-2018 versus 2005-2009, adjusted hazard ratio, 0.80; 95% confidence interval, 0.

28 exposed to mono-INH-resistant tuberculosis (adjusted hazard ratio, 0.80; 95% confidence interval, 0.

29 -0.84]; P<0.001) and lower 1-year mortality (adjusted hazard ratio, 0.812 per 1 gxmin/m(2) higher [95

30 ic treatment and 20.3 with guided treatment (adjusted hazard ratio, 0.95; 95% confidence interval [CI

31 the corresponding rates were 12.8 and 13.3 (adjusted hazard ratio, 0.97 [95% CI, 0.67 to 1.40]).

32 hazards ratio, 0.96 [95% CI, 0.75 to 1.24]; adjusted hazard ratio, 0.97 [95% CI, 0.76 to 1.25]).

33 mortality dissipated after risk adjustment (adjusted hazard ratio, 0.98 [95% CI, 0.94-1.02]).

34 effects Cox proportional hazard models, age (adjusted hazard ratio, 0.98; 95% CI [0.96-0.99]), anoxic

35 -fold reduction in cardiovascular mortality (adjusted hazard ratio: 0.10; p = 0.025).

36 an ~8-fold reduction in all-cause mortality (adjusted hazard ratio: 0.12; p = 0.001) and a ~10-fold r

37 compared with remaining on the waiting list (adjusted hazard ratio: 0.58; 95% confidence interval: 0.

38 001) and all-cause-mortality (7.6% vs. 9.7%; adjusted hazard ratio: 0.61; 95% confidence interval: 0.

39 However, women had lower mortality (adjusted hazard ratio: 0.68; 95% confidence interval: 0.

40 ipants were less likely to be listed for KT (adjusted hazard ratio: 0.70, 95% CI: 0.64-0.77, P < 0.00

41 en had a lower risk of MACE (9.5% vs. 11.2%; adjusted hazard ratio: 0.77; 95% confidence interval: 0.

42 fit associated with accepting an IRD kidney (adjusted hazard ratio: 0.791.723.73, P = 0.2).

43 370 of 2,044) and 15% (513 of 3,325) of men (adjusted hazard ratio: 0.85; 95% confidence interval: 0.

44 of death or HFH between 30 days and 2 years (adjusted hazard ratio: 0.91 per -5 mm Hg PASP; 95% confi

45 with a higher risk of AF as a single factor (adjusted hazard ratio 1.11, 95% confidence interval 1.08

46 pendently increase the risk of advanced CRN (adjusted hazard ratio 1.17; 95% CI 0.59-2.31).

47 roke compared with no intracranial stenosis (adjusted hazard ratio 1.43, 95% CI 1.04-1.96), the risk

48 nd 8637 (14.1%) non-frail patients had died [adjusted hazard ratio 1.60; 95% confidence interval (CI)

49 his was associated with increased mortality (adjusted hazard ratio 1.7, 95% CI 1.2-2.4; p=0.0042).

50 ependently associated with higher mortality (adjusted hazard ratios 1.09 [1.01-1.17] for mild FTR, 1.

51 losporine A had a higher risk of graft loss (adjusted hazard ratio = 1.26; P = 0.046).

52 ts aged >44 years and taking cyclosporine A (adjusted hazard ratio = 1.44; P = 0.011).

53 stimated 3-year event rate, 36.4% vs. 36.7%; adjusted hazard ratio, 1.01; 95% confidence interval [CI

54 fference in mortality between TAVR and SAVR (adjusted hazard ratio, 1.02 [95% CI, 0.91-1.15], P=0.7),

55 arm, which was not significantly different (adjusted hazard ratio, 1.07; 95% confidence interval, 0.

56 acquisition by day 14 (53 versus 45 events; adjusted hazard ratio, 1.10 [95% CI, 0.73 to 1.66]; P >

57 ference, -13.1 days [95% CI, -42.6 to 16.4]; adjusted hazard ratio, 1.13 [95% CI, 0.69 to 1.85]; P =

58 MELD score (adjusted hazard ratio, 1.13; 95% confidence interval, 1.

59 orrhage patients compared with these groups (adjusted hazard ratio, 1.14; 95% CI, 0.98-1.33 and adjus

60 wer in ischemic stroke compared with sepsis (adjusted hazard ratio, 1.21; 95% CI, 1.06-1.36) and seve

61 controlled) had a higher risk of CVD events (adjusted hazard ratio, 1.21; 95% confidence interval, 1.

62 ated with increased risk of all-cause death (adjusted hazard ratio, 1.29 [95% CI, 1.03-1.62]), major

63 ; 95% CI: 1.2, 1.4; P < .001) and non-White (adjusted hazard ratio, 1.2; 95% CI: 1.1, 1.3; P < .001)

64 lar death, myocardial infarction, or stroke (adjusted hazard ratio, 1.30 [95% CI, 1.05-1.62]), all P<

65 ase patients had 31% higher hazard of death (adjusted hazard ratio, 1.31; 95% CI, 1.17-1.47; p < 0.00

66 For both White (adjusted hazard ratio, 1.3; 95% CI: 1.2, 1.4; P < .001)

67 1 [95% CI, 1.7-2.5]; P<0.001) and at 1 year (adjusted hazard ratio, 1.4 [95% CI, 1.3-1.6]; P<0.001).

68 in survival at 6 years (80.9% versus 85.8%%, adjusted hazard ratio, 1.44 [0.90-2.31]), but HCR had hi

69 ed hazard ratio, 1.14; 95% CI, 0.98-1.33 and adjusted hazard ratio, 1.49; 95% CI, 1.28-1.73).

70 atic decompensations in patients with DACLD (adjusted hazard ratio, 1.4; 95% confidence interval: 0.9

71 36) and severe community-acquired pneumonia (adjusted hazard ratio, 1.57; 95% CI, 1.39-1.77) and in i

72 trongest predictor of myocardial infarction (adjusted hazard ratio, 1.60 (95% CI, 1.10-2.34) per doub

73 kidney disease; TNFR-2 had the highest risk (adjusted hazard ratio, 1.61; 95% CI, 1.15 to 2.26).

74 isplatin and cetuximab groups, respectively (adjusted hazard ratio, 1.63; 95% CI, 0.93 to 2.86; P = .

75 than those in untreated HIV-positive women (adjusted hazard ratio, 1.63; 95% confidence interval, 1.

76 CI, 1.61-3.62]; P<0.001), LG-NF and DI<0.25 (adjusted hazard ratio, 1.84 [95% CI, 1.24-2.73]; P=0.003

77 lity excluding deaths during the first year (adjusted hazard ratio, 1.88 [1.10-3.23]).

78 ) of the participants with low genetic risk (adjusted hazard ratio, 1.91 [95% CI, 1.64-2.23]).

79 an follow-up 4.7 years) all-cause mortality (adjusted hazard ratio, 1.93 [95% CI, 1.37-2.73], P<0.001

80 survival for patients with these anomalies (adjusted hazard ratio, 1.96; P=0.06).

81 s not an independent predictor of mortality (adjusted hazard ratio: 1.02; 95% confidence interval: 0.

82 564] vs. stress testing: 1.3% [45 of 3,494]; adjusted hazard ratio: 1.03; 95% confidence interval: 0.

83 fore and after implementation, respectively (adjusted hazard ratio: 1.11; 95% confidence interval: 0.

84 ricarditis and control groups, respectively (adjusted hazard ratio: 1.31; 95% confidence interval: 1.

85 ose with PASP of <50 mm Hg (68.8% vs. 49.1%; adjusted hazard ratio: 1.52; 95% confidence interval: 1.

86 0.072), driven by events in the first 48 h (adjusted hazard ratio: 1.54; 95% CI: 1.07 to 2.23; p = 0

87 %) were significantly associated with death (adjusted hazard ratio: 1.75; 95% CI: 1.37 to 2.24; p < 0

88 redicted progression to psychotic disorders (adjusted hazard ratio=1.10, 95% CI=1.04, 1.16).

89 95% CI=3.53, 7.14) and psychotic disorders (adjusted hazard ratio=1.63, 95% CI=1.30, 2.06).

90 positive than in those who tested negative (adjusted hazard ratio, 12.2; 95% confidence interval: 4.

91 mortality was significantly higher <30 days (adjusted hazard ratio: 15.7; 95% confidence interval: 12

92 r with systematic treatment (17.4% vs. 7.2%; adjusted hazard ratio 2.57; 95% CI, 1.75 to 3.78).

93 of 125) for children 5 to <11 years of age (adjusted hazard ratio = 2.05; 95% confidence interval =

94 ints versus the hospitalized cohort (year 5: adjusted hazard ratio, 2.00; 95% CI, 1.80-2.23) and the

95 sure of greater than 80% of monitoring time (adjusted hazard ratio, 2.13; 95% CI, 1.04-4.41; p = 0.04

96 1.24-2.73]; P=0.003), and LG-LF and D>=0.25 (adjusted hazard ratio, 2.27 [95% CI, 1.42-3.63]; P<0.001

97 was associated with a higher risk of death (adjusted hazard ratio, 2.2; 95% confidence interval, 1.1

98 orter DDFS (for distant recurrence or death, adjusted hazard ratio, 2.31; 95% CI, 1.05 to 5.06; P = .

99 pared with patients with LG-NF and DI>=0.25 (adjusted hazard ratio, 2.41 [95% CI, 1.61-3.62]; P<0.001

100 terial blood pressure of more than 10 mm Hg (adjusted hazard ratio, 2.44; 95% CI, 1.21-4.92; p = 0.01

101 who developed preeclampsia during pregnancy (adjusted hazard ratio, 2.68; 95% confidence interval, 1.

102 d of future CV or death event (multivariable-adjusted hazard ratio: 2.03; 95% confidence interval: 1.

103 RIR remained strongly associated with MACCE (adjusted hazard ratio: 2.10; 95% confidence interval: 1.

104 val: 12.3 to 20.0) and 30 days to 12 months (adjusted hazard ratio: 2.7; 95% confidence interval: 2.1

105 creased risk of later psychiatric diagnoses (adjusted hazard ratio=2.76, 95% CI=1.48, 5.13).

106 ence in both uni- and multivariate analysis (adjusted hazard ratio 3.05 and 1.88, respectively).

107 ustment for known risk factors of mortality (adjusted hazard ratio 3.25, 95% CI 1.49-7.10; P = .003).

108 ependently associated with excess mortality (adjusted Hazard Ratio = 3.41; 95%CI, 1.55-7.51; p=.002).

109 increased all-cause mortality (12-month risk-adjusted hazard ratio, 3.41 [95% CI, 1.81-6.41]; P<0.001

110 ) and the general population cohort (year 5: adjusted hazard ratio, 3.52; 95% CI, 3.23-3.83).

111 redictive of a first hepatic decompensation (adjusted hazard ratio, 3.7; 95% confidence interval: 1.1

112 : 2.7, 20.2; P < .001) and those with DACLD (adjusted hazard ratio, 3.8; 95% confidence interval: 1.7

113 iated with increased long-term risk for VTE (adjusted hazard ratio: 3.13; 95% confidence interval: 2.

114 T had a higher risk of developing cirrhosis (adjusted hazard ratio: 3.37; 95% CI: 2.34-4.86; P < 0.01

115 nt mental health services before ages 16-17 (adjusted hazard ratio=3.13, 95% CI=1.93, 5.07).

116 a higher risk compared with moderate group (adjusted hazard ratio 4.95 [2.02-12.13] and 2.78 [1.07-7

117 hosis was strongly associated with HCC risk (adjusted hazard ratio = 4.13, 95% confidence interval =

118 1.29 [95% CI, 1.03-1.62]), major amputation (adjusted hazard ratio, 4.12 [95% CI, 2.46-6.88]), and a

119 .37 to 6.55 per 100 person-years at 2 years (adjusted hazard ratio, 4.8 [95% CI, 3.5-6.5]; P<0.001).

120 t increased risk of an unsuccessful outcome (adjusted hazard ratio, 4.8; 95% CI, 2.1-10.9).

121 lar for HF with preserved ejection fraction (adjusted hazard ratio: 4.71; 95% CI: 2.94 to 7.52) and H

122 LD was an independent predictor of diabetes (adjusted hazard ratio, 5.13; 95% confidence interval, 2.

123 7.52) and HF with reduced ejection fraction (adjusted hazard ratio: 5.53; 95% confidence interval: 3.

124 y predicted progression to bipolar disorder (adjusted hazard ratio=5.02, 95% CI=3.53, 7.14) and psych

125 r for mortality in both patients with CACLD (adjusted hazard ratio, 7.4; 95% confidence interval: 2.7

126 kelihood of having an approved living donor (adjusted hazard ratio, 7.74; 95% confidence interval, 3.

127 chotic experiences or diagnosis at baseline (adjusted hazard ratio=7.85, 95% CI=3.94, 15.63), but hav

128 to GA compared with when it did not develop (adjusted hazard ratio, 78.1; 95% CI, 13.6-448.0; P < 0.0

129 1%, p = 0.02) and elective discontinuation (adjusted hazard ratio: 8.75, 95% CI 3.08-24.8, p < 0.001

130 ed with increased risk of colorectal cancer (adjusted hazard ratios 9.25; 95% confidence interval [CI

131 eased likelihood of living donor screenings (adjusted hazard ratio, 9.27; 95% confidence interval, 5.

132 s-CVD phenotype, the effect of OSA showed an adjusted hazard ratio (95% confidence interval) of 1.54

133 of cardiovascular disease, the multivariable-adjusted hazard ratios (95% confidence intervals) for in

134 most double the risk of all-cause mortality (adjusted hazard ratio [95% confidence interval], 1.91 [1

135 risk for each possible medication stepdown (adjusted hazard ratio, 95% CI, p-value: ICS inhaler dose

136 y allograft failure and death (multivariable-adjusted hazard ratio, (95%LCL) aHR(95%UCL) ), over foll

137 utpatient visits (3+ vs 0 outpatient visits: adjusted hazard ratio (adjHR), 1.56; 99% confidence inte

138 ated with an increased hazard of recurrence (adjusted hazard ratio [adjHR], 1.41; 95% CI, 0.98 to 2.0

139 smokers had a similar 1-year risk of death (adjusted hazard ratio [adjHR]: 0.92; 95% CI: 0.46 to 1.8

140 ociated with all-cause mortality at 90 days (adjusted hazard ratio [adjHR]: 1.47 per 1 SD increase; 9

141 c origin (sub-Saharan African vs. Caucasian, adjusted hazard ratio [adjHR]: 1.95; 95% CI: 1.13 to 3.3

142 ignificantly lower pre-transplant mortality (adjusted Hazard Ratio aHR 0.70, 95% CI 0.54-0.91, p-valu

143 elihood of LDKT increased by 70% for whites [adjusted hazard ratio (aHR) 1.70; 95% confidence interva

144 associated with a 46% greater risk of T2MI (adjusted hazard ratio (aHR) = 1.46, 95% confidence inter

145 ansplantation were associated with increased adjusted hazard ratio (aHR) for MACCE or all-cause morta

146 than in the underweight population, with an adjusted hazard ratio (AHR) of 0.5 (95% CI 0.4-0.7, p <

147 Cox proportional hazards model to derive an adjusted hazard ratio (aHR).

148 ) and persisted on adjusted analyses [kidney adjusted hazard ratio (aHR): 0.58, 95% confidence interv

149 Adjusted hazard ratios (aHR) with 95% confidence interva

150 h-dimensional propensity scores, to generate adjusted hazard ratios (aHR).

151 D50 offers had 49% decreased mortality risk (adjusted hazard ratio [aHR] (0.46) 0.51(0.55) , cumulati

152 ension had no higher risk for graft failure (adjusted hazard ratio [aHR] 1.03, 95% confidence interva

153 In the multivariable Cox model, older age (adjusted hazard ratio [aHR] 1.31 [1.09-1.57] per 10-year

154 ong people with HIV after adjusting for age (adjusted hazard ratio [aHR] 1.47, 95% confidence interva

155 Having HIV (adjusted hazard ratio [aHR] 2.1, 95% confidence interval

156 HIV was associated with COVID-19 mortality (adjusted hazard ratio [aHR] 2.14; 95% confidence interva

157 a 2.6-fold increase in kidney graft failure (adjusted hazard ratio [aHR] 2.63, P < 0.001), 1.6-fold i

158 CD4+ count (>=350 cells/ul vs <200 cells/ul [adjusted hazard ratio [aHR] = 0.35, 95% CI: .15-.84; I2

159 ng the clinical factors, immunosuppressants (adjusted hazard ratio [aHR] = 0.408 [95% confidence inte

160 falls (6.5%) had a lower chance of listing (adjusted hazard ratio [aHR] = 0.68, 95% confidence inter

161 nt difference in the risks of graft failure (adjusted hazard ratio [aHR] = 0.861.001.17), death (aHR

162 gnificantly increased risk of graft failure (adjusted hazard ratio [aHR] = 1.6; P = .001) but not of

163 iding in areas of short relapse periodicity (adjusted hazard ratio [AHR] = 6.2, 95% CI 2.0-19.5; p =

164 ents (5-year ACGL: 45.5% vs 10.6%; P < 0.01; adjusted hazard ratio [aHR] any impairment, 5.40 (95% co

165 develop prostate disorder after adjustment (adjusted hazard ratio [aHR] of 2.590 to 2.641 by competi

166 variables, including RV function, both TRF (adjusted hazard ratio [AHR] per 10% increment: 1.26; 95%

167 for ART dropout if they were from the south (adjusted hazard ratio [aHR] range from 1.91, 95% CI 1.71

168 ants with baseline CD4 count >=500 cells/uL (adjusted hazard ratio [aHR], 0.23; P = .045) and 3-fold

169 o PDR was associated with longer time to VS (adjusted hazard ratio [aHR], 0.32; 95% confidence interv

170 on (for 2 to 5 years vs. less than 6 months: adjusted hazard ratio [aHR], 0.61; 95% CI, 0.44-0.83), b

171 igher in HIV-infected versus HIV-uninfected (adjusted hazard ratio [aHR], 1.41; P < 0.001).

172 ve oral antibiotic therapy on AMA discharge (adjusted hazard ratio [aHR], 2.32; 95% confidence interv

173 ed CT-positive had an increased risk of PID (adjusted hazard ratio [aHR], 2.36; 95% confidence interv

174 of any subsequent substance misuse outcomes (adjusted hazard ratio [aHR], 3.11; 95% confidence interv

175 Baseline OcC (adjusted hazard ratio [aHR], 7.1 [95% CI, 1.3-38.0]) and

176 % [n = 121 of 538] vs 16.1% [n = 89 of 554]; adjusted hazard ratio [aHR],1.46; 95% confidence interva

177 slated to a 2.22-fold higher mortality risk (adjusted hazard ratio [aHR]: (2.15) 2.22(2.29) , P < .00

178 associated with lower in-hospital mortality (adjusted hazard ratio [aHR]: 0.53; 95% confidence interv

179 sociated with a lower risk of CMV infection (adjusted hazard ratio [aHR]: 0.63; 95% confidence interv

180 S recipients had no difference in mortality (adjusted hazard ratio [aHR]: 0.861.623.06, P = 0.1), dea

181 S recipients had no difference in mortality (adjusted hazard ratio [aHR]: 0.861.623.06, p=0.1), death

182 r was associated with lower all-cause death (adjusted hazard ratio [aHR]: 0.95 per 10% decrease in LV

183 Male sex (adjusted hazard ratio [aHR]: 1.63; 95% confidence interv

184 eriod within the first month posttransplant (adjusted hazard ratio [aHR]: 2.493.494.89, P < 0.001), b

185 heart recipients had the highest risk (3.13 adjusted hazard ratio [aHR]; 95% CI: 1.53-6.40) for obes

186 ease in mortality compared to non-elderlies (adjusted hazard ratio[aHR] 4.79, p<0.001).

187 Cox regression was used to estimate adjusted hazard ratio (aHRs) and 95% confidence interval

188 nal hazards models were used to evaluate the adjusted hazard ratios (aHRs) and 95% confidence interva

189 azards regression to estimate unadjusted and adjusted hazard ratios (aHRs) and 95% confidence interva

190 Cox regression was used to compute adjusted hazard ratios (aHRs) for IHD associated with pr

191 We modeled adjusted hazard ratios (aHRs) for OM comparing 7-valent

192 The adjusted hazard ratios (aHRs) for the primary composite

193 We calculated adjusted hazard ratios (aHRs) with 95% CIs for associati

194 using a competing risks analysis to estimate adjusted hazard ratios (aHRs).

195 onitoring and medication dispensing reviews (adjusted hazard ratios [aHRs], 1.34 to 1.40; P values <

196 Sex- and race-specific multivariable-adjusted hazard ratios and 95% confidence intervals were

197 Cox regression analyses showed that case-mix adjusted hazard ratios during the follow-up period of up

198 r predicted progression to bipolar disorder (adjusted hazard ratio for a one-standard-deviation incre

199 s index of 0.87 kg/m(2), and the age and sex-adjusted hazard ratio for aortic valve stenosis was 1.3

200 used rivaroxaban in 0% to 20% of cases, the adjusted hazard ratio for bleeding was 1.06 when treated

201 perienced a DGF duration of 1 to 4 days, the adjusted hazard ratio for duration of 5 to 7, 8 to 13, a

202 The adjusted hazard ratio for exacerbation in the comparison

203 eatment effect for female and male patients (adjusted hazard ratio for females: 0.90 [95% confidence

204 Compared with participants without LVH, the adjusted hazard ratio for HF was 2.8 (95% CI, 2.1-3.5) i

205 The adjusted hazard ratio for hospitalization for COPD was 1

206 higher lipoprotein(a) level the age- and sex-adjusted hazard ratio for ischemic stroke was 1.20 (95%

207 first to 50th percentile), the multivariable-adjusted hazard ratio for ischemic stroke was 1.60 (95%

208 patients with a history of hypertension, the adjusted hazard ratio for MACE was 0.94, 95% CI, 0.82-1.

209 In contrast, the adjusted hazard ratio for major amputations was 1.00 (95

210 was 0.94, 95% CI, 0.82-1.08; P=0.39, and the adjusted hazard ratio for MALE was 1.08, 95% CI, 0.96-1.

211 .90 [95% confidence interval: 0.54 to 1.51]; adjusted hazard ratio for males: 0.76 [95% confidence in

212 ficantly increased risk for all-cause death (adjusted hazard ratio for moderate and severe degrees of

213 ents on waitlist eGFR >=60 mL/min/1.73m, the adjusted hazard ratio for mortality was 1.04 (0.98-1.11)

214 128,861 patients with HIV-1 or hepatitis B (adjusted hazard ratio for NRTI exposure, 0.673; 95% conf

215 ger in the primary prevention cohort with an adjusted hazard ratio for the top versus lowest tertile

216 The adjusted hazard ratio for vancomycin versus all other co

217 The age- and sex-adjusted hazard ratios for ASCVD events among patients w

218 mL.g(-1).min(-1) decrease in stress MBF, the adjusted hazard ratios for death and MACE were 1.93 (95%

219 For each 1 U decrease in MPR, the adjusted hazard ratios for death and MACE were 2.45 (95%

220 Adjusted hazard ratios for DFS and OS were, respectively

221 ared with those without SDH, crude and fully adjusted hazard ratios for fatal incident CHD among thos

222 The adjusted hazard ratios for high (vs.

223 was included in a landmark-model to estimate adjusted hazard ratios for mortality.

224 Per 1-mmol/l higher levels, multivariable-adjusted hazard ratios for myocardial infarction were 2.

225 hazards models, we estimated unadjusted and adjusted hazard ratios for the association between mater

226 not receive a target antibiotic (4.6%), the adjusted hazards ratios for piperacillin/tazobactam, cef

227 The adjusted hazard ratio from the multivariable Cox regress

228 g all-cause or Alzheimer's disease dementia, adjusted hazard ratio (HR) 0.61 [95% confidence interval

229 us was not associated with tumor recurrence [adjusted hazard ratio (HR) 1.02, 95% confidence interval

230 as independently associated with graft loss [adjusted hazard ratio (HR) 1.03 for every 10-minute incr

231 reater risk for breast cancer (multivariable-adjusted hazard ratio (HR) = 1.32, 95% confidence interv

232 up (24.1% versus 7.1% [oral RBV], P = 0.03), adjusted hazard ratio (HR) for death and oral RBV use (c

233 The fully adjusted hazard ratio (HR) of dementia was 0.71 (95% con

234 = 340) in the nonsurgery group, with a lower adjusted hazard ratio (HR) of overall all-cause mortalit

235 Survival also improved in plasma recipients (adjusted hazard ratio (HR), 0.34; 95% CI, 0.13-0.89; chi

236 ents had lower rates of long-term mortality (adjusted hazard ratio (HR), 0.473; 95% CI, 0.392-0.571;

237 % increased risk of poor cognitive function [adjusted hazard ratio (HR): 1.051; 95% confidence interv

238 Multivariable Cox regression yielded adjusted hazard ratios (HR) and 95% confidence intervals

239 with a 60% decrease in the primary outcome (adjusted hazard ratio [HR] 0.4, P<0.001).

240 2.8) in the standard GVHD prophylaxis group (adjusted hazard ratio [HR] 0.56, 95% CI [0.35-0.90]; p=0

241 of 3421 participants in the polypill group (adjusted hazard ratio [HR] 0.66, 95% CI 0.55-0.80).

242 months (29.7-44.5) in the observation group (adjusted hazard ratio [HR] 0.81, 95% CI 0.63-1.04; p=0.0

243 for years living with HIV in three studies (adjusted hazard ratio [HR] 1.11, 95% CI 0.68-1.80; I(2)

244 CB symptoms after adjustment for covariates (adjusted hazard ratio [HR] = 1.17, p = 0.458 and HR = 1.

245 with a 60% decrease in the primary outcome (adjusted hazard ratio [HR], 0.4; P < .001).

246 red with 52% in those without a precipitant (adjusted hazard ratio [HR], 0.75 [95% CI, 0.69-0.81]; P<

247 djustment for age, sex, and medical history (adjusted hazard ratio [HR], 0.83 [95% CI, 0.67-1.03]).

248 No differences in DFS (adjusted hazard ratio [HR], 0.87; 95% CI, 0.61 to 1.23;

249 use mortality (35.8% vs 32.1%, respectively; adjusted hazard ratio [HR], 1.11 [95% CI, 1.07-1.14]), h

250 erences in the risk of all-cause graft loss (adjusted hazard ratio [HR], 1.16; 95% confidence interva

251 CV death, myocardial infarction, or stroke (adjusted hazard ratio [HR], 1.23 [95% CI, 0.97-1.56], P=

252 ute difference, 5.56% [95% CI, 5.04%-6.19%]; adjusted hazard ratio [HR], 1.33 [95% CI, 1.26-1.41]), i

253 justment for established prognostic factors (adjusted hazard ratio [HR], 1.55 [95% CI, 1.21-1.97]) an

254 k factors for spinal hematoma were male sex (adjusted hazard ratio [HR], 1.72; 95% CI, 1.15-2.56), th

255 trategy using the primary (2.7% versus 1.1%; adjusted hazard ratio [HR], 2.98 [95% CI, 1.87-4.73]) an

256 o did not have a stroke died (P < .001; risk-adjusted hazard ratio [HR], 6.1 [95% CI, 5.4-6.8]; P < .

257 erse probability of censoring weighting with adjusted hazard ratio [HR], 6.20; 95% confidence interva

258 with a significantly increased risk of MACE (adjusted hazard ratio [HR]: 1.05/Gy; 95% CI: 1.02 to 1.0

259 ciated with 5-year cardiovascular mortality (adjusted hazard ratio [HR]: 2.18 [95% CI: 1.13 to 4.23]

260 (20.1 vs. 5.0 events per 1,000 person-years; adjusted hazard ratio [HR]: 2.35; 95% confidence interva

261 (symptoms, LVEF, and LVESDi), baseline DBP (adjusted-hazard ratio [HR]: 0.79 [95% confidence interva

262 variable Cox regression was used to estimate adjusted hazard ratios (HRs) and 95% CIs of the relation

263 Adjusted hazard ratios (HRs) and 95% CIs were estimated

264 Covariate-adjusted hazard ratios (HRs) and 95% CIs were estimated

265 egression was used to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence interval

266 Unadjusted and adjusted hazard ratios (HRs) and 95% confidence interval

267 mixed-effects logistic models and estimated adjusted hazard ratios (HRs) for incident tuberculosis w

268 ion analyses were used to estimate crude and adjusted hazard ratios (HRs) for ION development with re

269 re and covariates were used to calculate the adjusted hazard ratios (HRs) of mortality with their 95%

270 45 and Up Study calculated the multivariable-adjusted hazard ratios (HRs) of sitting for each sitting

271 using multivariable Cox regression providing adjusted hazard ratios (HRs) with 95% confidence interva

272 sen and Gill model was used to calculate the adjusted hazard ratios (HRs), focusing on heavy alcohol

273 Compared with 2000 to 2004, the adjusted hazard ratios in 2013 to 2016 were 0.73 (95% CI

274 Multivariable-adjusted hazard ratios (MVHRs) and 95% CIs were calculat

275 er 90-day mortality (6% vs. 15%) with a risk adjusted hazard ratio of 0.27 (95%CI .09-0.88, p = .03).

276 s-CVD phenotype, the effect of OSA showed an adjusted hazard ratio of 0.69 (0.46-1.04; P value = 0.08

277 nal Early Warning Score implementation, with adjusted hazard ratio of 0.94 (0.84-1.05) and 0.90 (0.77

278 7 (95% CI, 1.04-1.53), in comparison with an adjusted hazard ratio of 1.06 (95% CI, 0.81-1.41) in sub

279 d with neomycin plus hydrocortisone, with an adjusted hazard ratio of 2.26 (95% confidence interval [

280 ASCA levels less than 34 IU/mL (80%) with an adjusted hazard ratio of 3.13 (95% CI, 1.11-8.82; P = 0.

281 od were higher among handgun owners, with an adjusted hazard ratio of 3.34 for all male owners as com

282 IC patients were hospitalized longer (adjusted hazard ratio of discharge, 0.86; 95% CI, .83-.8

283 The cause-specific adjusted hazard ratio of MACE for metformin was 0.80 (95

284 as, solid fuel use was associated with fully adjusted hazard ratios of 1.12 (95% CI: 1.04, 1.21) for

285 n the middle and top tertiles of the GRS had adjusted hazard ratios of 1.15 (95% CI, 0.98-1.36) and 1

286 s and breast cancer-specific mortality, with adjusted hazard ratios of 2.59 (95% CI, 1.01 to 6.67) fo

287 OPD, those with early COPD had multivariable adjusted hazard ratios of 6.42 (95% confidence interval,

288 ly associated with lower risk of overall HF (adjusted hazard ratio per 10% decrease in FM, 0.80 [95%

289 0% decrease in FM, 0.80 [95% CI, 0.68-0.95]; adjusted hazard ratio per 10% decrease in WC, 0.77 [95%

290 ial infarction, or urgent revascularization (adjusted hazard ratio quartile 4: quartile 1, 1.22; 95%

291 , transplant, and recipient characteristics (adjusted hazard ratio ranged from 0.96 to 1.01 per log-2

292 General Population Study, with multivariable adjusted hazard ratios up to 1.99 (95%confidence interva

293 The adjusted hazard ratio was highest in patients who underw

294 drink" as 12 g of ethanol, the multivariable-adjusted hazard ratios were 0.77 (95% confidence interva

295 th short-term use (3 months to <1 year), the adjusted hazard ratios were 0.90 (95% CI, 0.76 to 1.06)

296 For each 1-unit increase in BMI, similarly adjusted hazard ratios were 1.15 (95% CI, 1.14-1.17) for

297 algorithm as having any grade of emphysema (adjusted hazard ratios were 1.5, 1.7, 2.9, 5.3, and 9.7,

298 Adjusted hazard ratios were 2.53 (95% CI, 1.27-5.05) for

299 Multivariable-adjusted hazard ratios were estimated using Cox proporti

300 recorded in the year after delivery and the adjusted hazard ratio when comparing first-trimester vac